Related references
Note: Only part of the references are listed.PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
L. Paz-Ares et al.
Journal of Thoracic Oncology (2021)
Reframing recalcitrance for small-cell lung cancer
F. H. Blackhall
ANNALS OF ONCOLOGY (2021)
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
Anish Thomas et al.
CANCER CELL (2021)
Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors
Shixue Chen et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2020)
Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.
Santiago Ponce Aix et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Jose Trigo et al.
LANCET ONCOLOGY (2020)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
Nathalie Baize et al.
LANCET ONCOLOGY (2020)
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah et al.
LUNG CANCER (2020)
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
Wei Xie et al.
ONCOIMMUNOLOGY (2019)
Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials
S. Ponce et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line
Anna F. Farago et al.
FUTURE ONCOLOGY (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
Benjamin J. Drapkin et al.
CANCER DISCOVERY (2018)
Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE)
Shadia I. Jalal et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Marcello Tiseo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
E. Calvo et al.
ANNALS OF ONCOLOGY (2017)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Gema Santamaria Nunez et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
M. Catherine Pietanza et al.
CLINICAL CANCER RESEARCH (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
Nobuyuki Horita et al.
Scientific Reports (2015)
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
Maria Elena Elez et al.
CLINICAL CANCER RESEARCH (2014)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Charles M. Rudin et al.
NATURE GENETICS (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
J. F. M. Leal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R. Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production
P Allavena et al.
CANCER RESEARCH (2005)
Share Paper
